DNA repair pathways as targets for cancer therapy

T Helleday, E Petermann, C Lundin, B Hodgson… - Nature Reviews …, 2008 - nature.com
DNA repair pathways can enable tumour cells to survive DNA damage that is induced by
chemotherapeutic treatments; therefore, inhibitors of specific DNA repair pathways might …

[HTML][HTML] Imaging biomarker roadmap for cancer studies

JPB O'connor, EO Aboagye, JE Adams… - Nature reviews Clinical …, 2017 - nature.com
Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs
used daily in oncology include clinical TNM stage, objective response and left ventricular …

Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials

AS Strimpakos, RA Sharma - Antioxidants & redox signaling, 2008 - liebertpub.com
Curcumin is a natural polyphenol used in ancient Asian medicine. Since the first article
referring to the use of curcumin to treat human disease was published in The Lancet in …

Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance

RA Sharma, SA Euden, SL Platton, DN Cooke… - Clinical cancer …, 2004 - AACR
Curcumin, a polyphenolic antioxidant derived from a dietary spice, exhibits anticancer
activity in rodents and in humans. Its efficacy appears to be related to induction of …

Pharmacodynamic and Pharmacokinetic Study of Oral Curcuma Extract in Patients with Colorectal Cancer

RA Sharma, HR McLelland, KA Hill, CR Ireson… - Clinical Cancer …, 2001 - AACR
Curcuma spp. extracts, particularly the dietary polyphenol curcumin, prevent colon cancer in
rodents. In view of the sparse information on the pharmacodynamics and pharmacokinetics …

Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization …

A Kennedy, S Nag, R Salem, R Murthy… - International Journal of …, 2007 - Elsevier
PURPOSE: To standardize the indications, techniques, multimodality treatment approaches,
and dosimetry to be used for yttrium-90 (Y90) microsphere hepatic brachytherapy …

Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic …

G Garcea, DP Berry, DJL Jones, R Singh… - … Biomarkers & Prevention, 2005 - AACR
Curcumin, a constituent of the spice turmeric, has been shown to reduce the adenoma
burden in rodent models of colorectal cancer accompanied by a reduction of levels of the …

Pharmacokinetics and pharmacodynamics of curcumin

RA Sharma, WP Steward, AJ Gescher - … uses of curcumin in health and …, 2007 - Springer
Curcuma spp. contain turmerin, essential oils, and curcuminoids, including curcumin.
Curcumin [1, 7-bis-(4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione] is regarded as …

Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis

S Perkins, RD Verschoyle, K Hill, I Parveen… - … Biomarkers & Prevention, 2002 - AACR
Curcumin, the major yellow pigment in turmeric, prevents the development of adenomas in
the intestinal tract of the C57Bl/6J Min/+ mouse, a model of human familial APC. To aid the …

[HTML][HTML] First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE …

HS Wasan, P Gibbs, NK Sharma, J Taieb… - The Lancet …, 2017 - thelancet.com
Background Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent
therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver …